Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Sci Transl Med. 2013 Oct 16;5(207):207ps14. doi: 10.1126/scitranslmed.3006305.
Molecular analyses of circulating tumor DNA (ctDNA) in plasma from cancer patients have the potential to deliver minimally invasive diagnostic and disease-monitoring biomarkers. Drawing from experience gained through the translation of circulating tumor cell detection to clinical tests, we discuss ctDNA as a source of tumor material for biomarker development.
对癌症患者血浆中循环肿瘤 DNA（ctDNA）的分子分析有可能提供微创的诊断和疾病监测生物标志物。借鉴通过循环肿瘤细胞检测转化为临床检测获得的经验，我们讨论了 ctDNA 作为肿瘤标志物开发的肿瘤材料来源。
Zotero 插件